Raal, Frederick Johan
University of the Witwatersrand
South Africa
About
No AI summary yet.
Metrics
- Publications
- 547
- Citations
- 31.3K
- h-index
- 71
- Publishing journals
- 176
- Years of publications
- 20+
- Active since
- 2007
- References
- 12.6K
- Institutions
- 41
Publication history
Latest publications
- Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.
- ANGPTL3-lowering strategies to address residual cardiovascular risk.
- Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
- Homozygous Familial Hypercholesterolemia Treatment: New Developments
- Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry
- Homozygous Familial Hypercholesterolemia Is a Life-Limiting Condition
- Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice
- Obesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study
- Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
- Predictive diagnostic models for newly diagnosed diabetes mellitus in moderate to severe COVID-19: the role of TyG Index, BMI, and inflammatory markers
- MON-581 Predictive Models For New-onset Diabetes Mellitus In Covid-19: Evaluating Insulin Resistance And Inflammation
- SAT-255 Metabolic Implications Of Covid-19: Exploring Lipids And Inflammation
- Does evolocumab treatment reduce carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia?: Reply
- Abstract 4363704: YOSEMITE Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Zodasiran Efficacy and Safety in Adolescents and Adults with Homozygous Familial Hypercholesterolemia
- Baseline Characteristics And Response To Evinacumab In Women And Men With Homozygous Familial Hypercholesterolemia In The Elipse Ole Study
- Proposed lipidology and preventive cardiology research priorities in Africa; Results of a Delphi survey
- Ezetimibe in the management of homozygous familial hypercholesterolaemia
- Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary
- Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
- Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
No publications in the index yet.